908 Devices Trace Chemical Identification Technology Adopted by European Agencies
12 Mars 2024 - 12:00PM
Business Wire
Fostering Relationships with the NATO Support
and Procurement Agency and the DrugDetect EU project, 908 Devices’
MX908 Deployed Across Europe for Trace Chemical Detection and
Identification
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built
handheld and desktop devices for chemical and biochemical analysis,
announces the latest in international adoption of the MX908 for
trace detection and identification of priority drugs and chemical
threats. DrugDetect EU and NATO Support and Procurement Agency
(NSPA) have both entered into new contracts to deploy the MX908, a
handheld high-pressure mass spectrometry (HPMS) device. The MX908
will be used in a variety of settings, from military applications
to correctional facilities.
The DrugDetect EU project aims to quickly and effectively detect
a large range of drugs in correctional institutions and prisons in
several European countries to prevent drugs from entering and
circulating in facilities. A contract was awarded to 908 Devices
and the first two units shipped in recent months to Belgium and
Greece, with more units expected to be procured. Operational
validation demonstrated the effectiveness of the MX908 in detecting
and identifying trace amounts of drug samples, including cocaine,
heroin, methamphetamine and others. 908 Devices is also conducting
target development work for an additional 15 targets identified by
the DrugDetect EU project.
"The MX908 is an incredibly flexible device that quickly and
effectively identifies drugs and enables us to analyze results
quickly across our 34 prisons,” said Paul Van Tigchelt, Minister of
Justice, Belgium. “We’re committed to combatting drug use in our
prisons, and simultaneously protecting our staff, and the MX908
empowers our decision-making with peace of mind.”
In addition to the DrugDetect EU project, the NSPA contract is
significant as it streamlines the procurement process of the MX908
device for all 32 NATO member states and four additional countries.
Specifically, the agreement is valid for up to five years and
includes the ability to purchase up to approximately 80 units, of
which orders have already been fulfilled and more expected. NATO
countries and their allies can use the MX908 at the point of need
in a variety of environmental conditions and analyze trace level
samples in any state, including solid, liquid, gas/vapor and
aerosol. The device is frequently used for military CBRNE
applications.
“We’re honored to partner with the NATO Support and Procurement
Agency and DrugDetect EU project as they work to advance detection
and identification of chemical threats across Europe,” said Kevin
J. Knopp, CEO and co-founder of 908 Devices. “The versatility of
our technology empowers users with life-saving insights and our
customers are utilizing the MX908 on the frontlines to stem the
flow of drugs and other illicit substances to mitigate damage
throughout the region.”
The MX908 is a multi-mission handheld mass spectrometer utilized
by elite responders conducting chemical, explosive, priority drug
and HazMat operations around the world. Powered by HPMS and
featuring an evolving target list, the MX908 identifies compounds
at trace levels with a high level of sensitivity and unparalleled
selectivity to deliver quick, actionable insights to its users.
To learn more about 908 Devices, please visit:
908devices.com.
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis
with its simple handheld and desktop devices, addressing
critical-to-life applications. The Company’s devices are used at
the point-of-need to interrogate unknown and invisible materials
and provide quick, actionable answers to directly address some of
the most critical problems in life sciences research,
bioprocessing, pharma/biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic sampling and
separations, software automation, and machine learning.
About NSPA
The NATO Support and Procurement Agency (NSPA) is NATO’s lead
organization for multinational acquisition, support and sustainment
in all domains. NSPA is headquartered in the Grand Duchy of
Luxembourg, with main operational centres in France, Hungary and
Italy. The Agency employs over 1,500 staff and oversees more than
500 contractors worldwide.
About DrugDetect EU
The DrugDetect project aims to procure an innovative solution
for the automatic detection of a large range of drugs in
correctional institutions and prisons, that is available 24/7, does
not cause delays in internal processes, does not require minimal
human intervention, and is GDPR compliant. The DrugDetect project
receives co-funding by the COSME program of the European Union
under grant agreement No 101036225. The project’s partners include
the Center for Security Studies (KEMEA), the Custodial Institutions
Agency (DJI), the Directorate General of Penitentiary Institutions
(DG-EPI), and the Spanish Ministry of the Interior (ESMIR).
Forward Looking Statements for 908 Devices
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240312190110/en/
Media Contact Katie Johnston PAN Communications for 908
Devices 908devices@pancomm.com
Investor Contact Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
908 Devices (NASDAQ:MASS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024